Skip to main content
. 2024 Jun 22;131(4):676–684. doi: 10.1038/s41416-024-02773-w

Fig. 2. Efficacy to cis/carboplatin and etoposide and survival dependent on genetic alteration and NEC celltype.

Fig. 2

a Response to cis/carboplatin and etoposide according to TP53 status for LC-NEC (N = 61). b Immediate progression to cis/carboplatin and etoposide according to APC status for LC-NEC (N = 61). c Progression free survival (PFS) after cis/carboplatin and etoposide for LC-NEC according to APC status (N = 61). d Overall survival (OS) for SC-NEC according to TP53 status (N = 61).